Review



rna extraction utilized trizol  (Keygen Biotech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Keygen Biotech rna extraction utilized trizol
    Rna Extraction Utilized Trizol, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/reagent+trizol/pm42235066-60-0-4
    Average 86 stars, based on 1 article reviews
    rna extraction utilized trizol - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    cDNA Synthesis:

    Article Title: Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis.
    Article Snippet: Background: Metallothioneins (MTs) are crucial metal-binding proteins involved in cellular zinc homeostasis and oxidative stress response.. However, the role of metallothionein-related genes (MRGs) in breast cancer (BC) pathogenesis and their potential as therapeutic targets remains poorly understood.. Methods: We integrated two BC datasets, GSE42568 and GSE29044, to identify differentially expressed MRGs.

    Article Title: Remote Ischemic Preconditioning Enhances Skin Flap Survival via ZNF667/SDF1-Mediated Endothelial Progenitor Cells Functions for Angiogenesis.
    Article Snippet: .. From both cells and tissues, the total RNA was extracted using TRIzol reagent (KeyGEN BioTECH, KGA1201, China) and further reversed to cDNA using the First-strand cDNA synthesis kit from KeyGen BioTECH (KGA1316). qPCR was conducted using Realtime PCR Master Mix (SYBR Green) from KeyGen BioTECH (KGA1339). ..

    Real-time Polymerase Chain Reaction:

    Article Title: Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis.
    Article Snippet: Background: Metallothioneins (MTs) are crucial metal-binding proteins involved in cellular zinc homeostasis and oxidative stress response.. However, the role of metallothionein-related genes (MRGs) in breast cancer (BC) pathogenesis and their potential as therapeutic targets remains poorly understood.. Methods: We integrated two BC datasets, GSE42568 and GSE29044, to identify differentially expressed MRGs.

    Article Title: Remote Ischemic Preconditioning Enhances Skin Flap Survival via ZNF667/SDF1-Mediated Endothelial Progenitor Cells Functions for Angiogenesis.
    Article Snippet: .. From both cells and tissues, the total RNA was extracted using TRIzol reagent (KeyGEN BioTECH, KGA1201, China) and further reversed to cDNA using the First-strand cDNA synthesis kit from KeyGen BioTECH (KGA1316). qPCR was conducted using Realtime PCR Master Mix (SYBR Green) from KeyGen BioTECH (KGA1339). ..

    Polymerase Chain Reaction:

    Article Title: Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis.
    Article Snippet: Background: Metallothioneins (MTs) are crucial metal-binding proteins involved in cellular zinc homeostasis and oxidative stress response.. However, the role of metallothionein-related genes (MRGs) in breast cancer (BC) pathogenesis and their potential as therapeutic targets remains poorly understood.. Methods: We integrated two BC datasets, GSE42568 and GSE29044, to identify differentially expressed MRGs.

    Article Title: Remote Ischemic Preconditioning Enhances Skin Flap Survival via ZNF667/SDF1-Mediated Endothelial Progenitor Cells Functions for Angiogenesis.
    Article Snippet: .. From both cells and tissues, the total RNA was extracted using TRIzol reagent (KeyGEN BioTECH, KGA1201, China) and further reversed to cDNA using the First-strand cDNA synthesis kit from KeyGen BioTECH (KGA1316). qPCR was conducted using Realtime PCR Master Mix (SYBR Green) from KeyGen BioTECH (KGA1339). ..

    SYBR Green Assay:

    Article Title: Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis.
    Article Snippet: Background: Metallothioneins (MTs) are crucial metal-binding proteins involved in cellular zinc homeostasis and oxidative stress response.. However, the role of metallothionein-related genes (MRGs) in breast cancer (BC) pathogenesis and their potential as therapeutic targets remains poorly understood.. Methods: We integrated two BC datasets, GSE42568 and GSE29044, to identify differentially expressed MRGs.

    Article Title: Remote Ischemic Preconditioning Enhances Skin Flap Survival via ZNF667/SDF1-Mediated Endothelial Progenitor Cells Functions for Angiogenesis.
    Article Snippet: .. From both cells and tissues, the total RNA was extracted using TRIzol reagent (KeyGEN BioTECH, KGA1201, China) and further reversed to cDNA using the First-strand cDNA synthesis kit from KeyGen BioTECH (KGA1316). qPCR was conducted using Realtime PCR Master Mix (SYBR Green) from KeyGen BioTECH (KGA1339). ..

    RNA Extraction:

    Article Title: Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in Glioblastoma.
    Article Snippet: Glioblastoma (GBM) response to Temozolomide (TMZ) critically depends on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.. Clinically, the unmethylated MGMT subtype�representing the predominant GBM population�universally develops TMZ resistance, driving an urgent need for novel therapeutics.. While metabolic reprogramming represents a potential therapeutic target, current methylation detection methods cannot provide targetable metabolic information.

    Generated:

    Article Title: Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in Glioblastoma.
    Article Snippet: Glioblastoma (GBM) response to Temozolomide (TMZ) critically depends on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.. Clinically, the unmethylated MGMT subtype�representing the predominant GBM population�universally develops TMZ resistance, driving an urgent need for novel therapeutics.. While metabolic reprogramming represents a potential therapeutic target, current methylation detection methods cannot provide targetable metabolic information.

    Quantitative RT-PCR:

    Article Title: Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in Glioblastoma.
    Article Snippet: Glioblastoma (GBM) response to Temozolomide (TMZ) critically depends on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.. Clinically, the unmethylated MGMT subtype�representing the predominant GBM population�universally develops TMZ resistance, driving an urgent need for novel therapeutics.. While metabolic reprogramming represents a potential therapeutic target, current methylation detection methods cannot provide targetable metabolic information.

    CCK-8 Assay:

    Article Title: Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer
    Article Snippet: Hydrochloric acid (HCl), chloroform (CHCl3), and isopropanol (IPA, C3H8O) were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). .. DMEM, serum, CCK-8 reagent, Trizol reagent, DEPC water, and phosphate-buffered solution (PBS, 1×, pH 7.4) were purchased from KeyGEN Biotechnology Co. (Nanjing, China). .. Reverse transcription reagent HiScript III was purchased from Nanjing Novozymes Biotech Co., Ltd. (Vazyme R333-C1, Nanjing, China), and SYBR green master mix was purchased from BioEasy BSB113S1 (Hangzhou, China).

    Concentration Assay:

    Article Title: Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer
    Article Snippet: .. Total RNA was extracted using Trizol reagent (KeyGEN BioTECH Co., China) according to the manufacturer’s protocol, and RNA concentration and purity were determined with a Porabio Pono-500 spectrophotometer. .. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using HiScript III reverse transcriptase (Vazyme, R333-C1, Nanjing, China).

    Article Title: Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer
    Article Snippet: .. Total RNA was extracted using Trizol reagent (KeyGEN BioTECH Co., China) according to the manufacturer’s protocol, and RNA concentration and purity were determined with a Porabio Pono-500 spectrophotometer. .. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using HiScript III reverse transcriptase (Vazyme, R333-C1, Nanjing, China).

    Spectrophotometry:

    Article Title: Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer
    Article Snippet: .. Total RNA was extracted using Trizol reagent (KeyGEN BioTECH Co., China) according to the manufacturer’s protocol, and RNA concentration and purity were determined with a Porabio Pono-500 spectrophotometer. .. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using HiScript III reverse transcriptase (Vazyme, R333-C1, Nanjing, China).

    Article Title: Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer
    Article Snippet: .. Total RNA was extracted using Trizol reagent (KeyGEN BioTECH Co., China) according to the manufacturer’s protocol, and RNA concentration and purity were determined with a Porabio Pono-500 spectrophotometer. .. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using HiScript III reverse transcriptase (Vazyme, R333-C1, Nanjing, China).



    Similar Products

    delsys trigno development kit  (Delsys Inc)
    94
    Delsys Inc delsys trigno development kit
    Delsys Trigno Development Kit, supplied by Delsys Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/Trigno+Control+Utility/pm42900225-76-15-15
    Average 94 stars, based on 1 article reviews
    delsys trigno development kit - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling  (DiaSorin Biotechnology)
    99
    DiaSorin Biotechnology 200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling
    200 Suspension Chip Multiplex Detection System Utilizes Bead Based Dual Fluorescence Labeling, supplied by DiaSorin Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/Luminex+200+System/10__1007_slash_s10989___026___10866___8-216-2-1
    Average 99 stars, based on 1 article reviews
    200 suspension chip multiplex detection system utilizes bead based dual fluorescence labeling - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    rna seq utilizes illumina sequencing  (Plasmidsaurus)
    99
    Plasmidsaurus rna seq utilizes illumina sequencing
    Rna Seq Utilizes Illumina Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/RNA-Seq/pm42595906-538-2-1
    Average 99 stars, based on 1 article reviews
    rna seq utilizes illumina sequencing - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    pradhan mantri jan arogya yojana increased utilization  (Arogya Inc)
    86
    Arogya Inc pradhan mantri jan arogya yojana increased utilization
    Pradhan Mantri Jan Arogya Yojana Increased Utilization, supplied by Arogya Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/arogya+jan+mantri+pradhan+yojana/pmc13264029-37-9-12
    Average 86 stars, based on 1 article reviews
    pradhan mantri jan arogya yojana increased utilization - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    immunohistochemical staining utilized pcna  (ABclonal Biotechnology)
    93
    ABclonal Biotechnology immunohistochemical staining utilized pcna
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Immunohistochemical Staining Utilized Pcna, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/PCNA+Mouse+mAb/pmc13526793-823-0-8
    Average 93 stars, based on 1 article reviews
    immunohistochemical staining utilized pcna - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    quantitative pcr process utilized chamq sybr qpcr master mix  (Vazyme Biotech Co)
    99
    Vazyme Biotech Co quantitative pcr process utilized chamq sybr qpcr master mix
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Quantitative Pcr Process Utilized Chamq Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/ChamQ+SYBR+qPCR+Master+Mix/pm41413714-56-1-11
    Average 99 stars, based on 1 article reviews
    quantitative pcr process utilized chamq sybr qpcr master mix - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    statistical processing utilized graphpad prism 8  (GraphPad Software Inc)
    99
    GraphPad Software Inc statistical processing utilized graphpad prism 8
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Statistical Processing Utilized Graphpad Prism 8, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/Prism+8/pm41980611-142-0-3
    Average 99 stars, based on 1 article reviews
    statistical processing utilized graphpad prism 8 - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    treatment utilized poractant alfa  (Chiesi)
    86
    Chiesi treatment utilized poractant alfa
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Treatment Utilized Poractant Alfa, supplied by Chiesi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/alfa+poractant/pm42316154-71-1-6
    Average 86 stars, based on 1 article reviews
    treatment utilized poractant alfa - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    utility  (Galectin Therapeutics)
    86
    Galectin Therapeutics utility
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Utility, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/pm42278921-240-3-5
    Average 86 stars, based on 1 article reviews
    utility - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    resource utilization  (Anhui Medical University)
    86
    Anhui Medical University resource utilization
    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
    Resource Utilization, supplied by Anhui Medical University, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/utility/resource+utilization/pm42265069-30-9-11
    Average 86 stars, based on 1 article reviews
    resource utilization - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy

    doi: 10.1038/s41467-026-76103-4

    Figure Lengend Snippet: a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

    Article Snippet: Immunohistochemical staining utilized PCNA (AC058, PCNA Mouse mAb, Abclonal) and Ki67 (A26755PM, Ki67 Rabbit PolymAb®, Abclonal) antibodies, with technical assistance from Nanjing Youmeng Biotechnology Co., Ltd. Tumor sections underwent immunofluorescence staining using a TUNEL assay kit (Beyotime Biotech, Shanghai, China).

    Techniques: Sequencing, Magnetic Resonance Imaging, Immunohistochemical staining